See more : Balfour Beatty plc (BAFYY) Income Statement Analysis – Financial Results
Complete financial analysis of Dynavax Technologies Corporation (DVAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dynavax Technologies Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- CVS Health Corporation (0HRS.L) Income Statement Analysis – Financial Results
- Bowl America Incorporated (BWL-A) Income Statement Analysis – Financial Results
- Seeing Machines Limited (SEE.L) Income Statement Analysis – Financial Results
- Good Works Acquisition Corp. (GWAC) Income Statement Analysis – Financial Results
- Locksley Resources Limited (LKY.AX) Income Statement Analysis – Financial Results
Dynavax Technologies Corporation (DVAX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.dynavax.com
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 232.28M | 722.68M | 439.44M | 46.55M | 35.22M | 8.20M | 327.00K | 11.04M | 4.05M | 11.03M | 11.25M | 9.71M | 21.61M | 23.95M | 40.32M | 37.09M | 14.09M | 4.85M | 14.66M | 14.81M | 826.00K | 1.43M | 2.36M | 0.00 |
| Cost of Revenue | 50.17M | 262.15M | 173.57M | 13.91M | 19.39M | 21.80M | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 299.00K | 980.00K | 980.00K | 980.00K | 1.00M | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 182.12M | 460.53M | 265.87M | 32.64M | 15.83M | -13.60M | -867.00K | 11.04M | 4.05M | 11.03M | 11.25M | 9.71M | 21.32M | 22.97M | 39.34M | 36.11M | 13.09M | 4.15M | 14.66M | 14.81M | 826.00K | 1.43M | 2.36M | 0.00 |
| Gross Profit Ratio | 78.40% | 63.73% | 60.50% | 70.12% | 44.95% | -165.87% | -265.14% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 98.62% | 95.91% | 97.57% | 97.36% | 92.88% | 85.60% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 54.89M | 46.60M | 32.23M | 28.61M | 62.33M | 74.95M | 64.99M | 84.49M | 86.94M | 84.58M | 50.87M | 49.15M | 51.32M | 53.68M | 38.71M | 44.77M | 65.89M | 50.12M | 27.89M | 23.13M | 14.38M | 15.97M | 17.36M | 8.27M |
| General & Administrative | 152.95M | 131.41M | 100.16M | 79.26M | 48.72M | 64.77M | 27.37M | 37.26M | 22.18M | 17.76M | 26.87M | 28.16M | 17.57M | 16.88M | 15.75M | 15.46M | 18.29M | 14.84M | 9.26M | 8.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 24.76M | 26.27M | 31.76M | 7.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 152.95M | 131.41M | 100.16M | 79.26M | 74.99M | 64.77M | 27.37M | 37.26M | 22.18M | 17.76M | 26.87M | 28.16M | 17.57M | 16.88M | 15.75M | 15.46M | 18.29M | 14.84M | 9.26M | 8.54M | 4.21M | 4.12M | 4.53M | 3.45M |
| Other Expenses | 11.31M | 7.80M | 8.66M | 6.81M | 3.35M | -70.00K | -486.00K | -2.49M | 317.00K | 433.00K | -348.00K | -293.00K | 299.00K | 980.00K | 980.00K | 980.00K | 1.00M | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 219.15M | 178.01M | 132.38M | 107.86M | 137.32M | 139.72M | 93.55M | 121.75M | 109.12M | 102.34M | 77.74M | 77.31M | 69.19M | 71.54M | 55.43M | 61.21M | 85.19M | 65.65M | 37.15M | 31.67M | 18.59M | 20.09M | 21.89M | 11.72M |
| Cost & Expenses | 269.31M | 440.16M | 305.96M | 121.77M | 156.71M | 161.52M | 93.55M | 121.75M | 109.12M | 102.34M | 77.74M | 77.31M | 69.19M | 71.54M | 55.43M | 61.21M | 85.19M | 65.65M | 37.15M | 31.67M | 18.59M | 20.09M | 21.89M | 11.72M |
| Interest Income | 31.99M | 7.91M | 140.00K | 1.26M | 3.37M | 3.83M | 1.34M | 755.00K | 205.00K | 191.00K | 116.00K | 291.00K | 103.00K | 85.00K | 112.00K | 1.74M | 4.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.76M | 6.73M | 11.18M | 19.06M | 16.98M | 9.34M | 0.00 | 0.00 | 572.00K | 35.00K | 0.00 | 2.35M | 1.96M | 1.65M | 124.00K | 9.16M | 1.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.28M | 6.67M | 7.01M | 9.34M | 21.53M | 14.48M | 4.44M | 2.26M | 1.37M | 1.40M | 1.33M | 1.21M | 1.60M | 2.40M | 2.84M | 2.83M | 632.00K | 1.53M | 3.13M | 3.27M | 576.00K | 678.00K | 0.00 | -2.05M |
| EBITDA | 9.67M | 307.70M | 95.71M | -46.84M | -114.09M | -135.08M | -90.72M | -110.19M | -104.86M | -89.28M | -65.39M | -66.39M | -45.04M | -53.26M | -12.17M | -21.29M | -71.09M | -60.67M | -19.36M | -15.44M | -17.19M | -17.98M | -19.53M | -11.72M |
| EBITDA Ratio | 4.16% | 41.27% | 32.38% | -144.26% | -325.87% | -1,824.36% | -27,292.05% | -1,002.51% | -2,581.51% | -822.04% | -579.16% | -695.88% | -216.57% | -154.67% | -30.45% | -70.87% | -497.32% | -1,136.60% | -132.09% | -91.73% | -2,080.87% | -1,260.06% | -827.94% | 0.00% |
| Operating Income | -37.03M | 283.52M | 134.49M | -75.22M | -121.49M | -153.32M | -96.01M | -110.71M | -105.07M | -91.31M | -66.49M | -67.60M | -47.58M | -47.59M | -15.12M | -24.12M | -71.09M | -64.98M | -22.49M | -16.86M | -17.76M | -18.66M | -19.53M | -9.66M |
| Operating Income Ratio | -15.94% | 39.23% | 30.60% | -161.59% | -344.95% | -1,870.20% | -29,359.33% | -1,002.51% | -2,594.40% | -827.69% | -590.95% | -695.86% | -220.12% | -198.70% | -37.49% | -65.02% | -504.45% | -1,340.68% | -153.46% | -113.83% | -2,150.61% | -1,307.57% | -827.94% | 0.00% |
| Total Other Income/Expenses | 32.66M | 10.78M | -56.97M | -6.87M | -17.76M | -5.58M | 851.00K | -1.74M | -1.72M | 589.00K | -232.00K | -2.35M | -1.02M | -9.72M | -12.00K | -2.42M | 2.45M | 3.19M | 1.94M | 889.00K | -274.00K | 0.00 | 19.53M | 0.00 |
| Income Before Tax | -4.37M | 294.30M | 77.52M | -75.24M | -152.60M | -158.90M | -95.15M | -112.44M | -106.79M | -90.72M | -66.72M | -69.95M | -48.60M | -57.31M | -30.57M | -20.83M | -59.97M | -52.05M | -20.56M | -15.97M | -18.04M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -1.88% | 40.72% | 17.64% | -161.63% | -433.29% | -1,938.27% | -29,099.08% | -1,018.24% | -2,636.89% | -822.35% | -593.01% | -720.08% | -224.84% | -239.28% | -75.81% | -56.15% | -425.54% | -1,073.90% | -140.26% | -107.82% | -2,183.78% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.02M | 1.14M | 808.00K | 16.54M | -1.20M | 3.76M | 1.45M | -3.01M | -476.00K | -936.00K | -116.00K | 851.00K | 1.02M | 9.72M | 0.00 | -3.29M | 372.00K | -8.75M | 0.00 | 0.00 | -686.00K | -621.00K | 18.41M | 17.06M |
| Net Income | -6.39M | 293.16M | 76.71M | -91.78M | -151.40M | -158.90M | -95.15M | -112.44M | -106.79M | -90.72M | -66.72M | -69.95M | -48.60M | -57.31M | -30.57M | -20.83M | -59.97M | -52.05M | -20.56M | -15.97M | -17.35M | -18.04M | -18.41M | -26.72M |
| Net Income Ratio | -2.75% | 40.56% | 17.46% | -197.15% | -429.87% | -1,938.27% | -29,099.08% | -1,018.24% | -2,636.89% | -822.35% | -593.01% | -720.08% | -224.84% | -239.28% | -75.81% | -56.15% | -425.54% | -1,073.90% | -140.26% | -107.82% | -2,100.73% | -1,264.05% | -780.50% | 0.00% |
| EPS | -0.05 | 2.32 | 0.62 | -0.91 | -2.10 | -2.55 | -1.81 | -2.92 | -3.25 | -3.45 | -3.40 | -4.10 | -3.88 | -6.95 | -7.57 | -5.23 | -15.09 | -16.10 | -7.93 | -7.54 | -96.88 | -106.04 | -122.91 | -225.90 |
| EPS Diluted | -0.05 | 1.97 | 0.54 | -0.91 | -2.10 | -2.55 | -1.81 | -2.92 | -3.25 | -3.45 | -3.40 | -4.10 | -3.88 | -6.95 | -7.57 | -5.23 | -15.09 | -16.10 | -7.93 | -7.54 | -96.24 | -106.04 | -122.91 | -225.90 |
| Weighted Avg Shares Out | 128.73M | 126.40M | 116.26M | 100.75M | 72.02M | 62.36M | 52.61M | 38.51M | 32.88M | 26.29M | 19.63M | 17.05M | 12.51M | 8.25M | 4.04M | 3.98M | 3.97M | 3.23M | 2.59M | 2.12M | 179.10K | 170.10K | 149.80K | 118.30K |
| Weighted Avg Shares Out (Dil) | 128.73M | 150.80M | 133.01M | 100.75M | 72.02M | 62.36M | 52.61M | 38.51M | 32.88M | 26.29M | 19.63M | 17.05M | 12.51M | 8.25M | 4.04M | 3.98M | 3.97M | 3.23M | 2.59M | 2.12M | 180.30K | 170.10K | 149.80K | 118.30K |
Dynavax Adopts Limited-Duration Stockholder Rights Plan
EMERYVILLE, Calif. , Oct. 29, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that its Board of Directors has adopted a limited-duration stockholder rights plan, effective immediately (the "Rights Plan").
Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024
EMERYVILLE, Calif. , Oct. 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets...
3 'Repeatable' Biotech Trades
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call...
Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Dynavax has experienced fluctuations in stock performance since the author's initial coverage. HEPLISAV-B is Dynavax's primary revenue source for the foreseeable future, with CpG-1018 currently sidelined. Supported by ample liquidity, Dynavax is evaluating business development on a disciplined basis.
How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 135.98%
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
Dynavax Technologies Corporation (DVAX) Q2 2024 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Cox - VP, Investor Relations & Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen -...
Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.
Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates
Achieved record quarterly HEPLISAV-B ® net product revenue of $70.2 million, growing 24% year-over-year Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million Initiated dosing in Phase 1/2 trial of novel shingles vaccine program with...
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the U.S. financial markets...
New Strong Sell Stocks for July 9th
BMWYY, DXC and DVAX have been added to the Zacks Rank #5 (Strong Sell) List on July 9, 2024.
Source: https://incomestatements.info
Category: Stock Reports